PDCD1 and melanoma: Currently, T-VEC combined with anti-CTLA-4 (ipilimumab) is studied in a phase II trial (NCT01740297) and combined with anti-PD-1 (pembrolizumab) in a phase Ib/III trail (NCT02263508), both in melanoma patients.